Literature DB >> 24452717

MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Xiao-hui Ling1, Zhao-dong Han, Dan Xia, Hui-chan He, Fu-neng Jiang, Zhuo-yuan Lin, Xin Fu, Ye-han Deng, Qi-shan Dai, Chao Cai, Jia-hong Chen, Yu-xiang Liang, Wei-de Zhong, Chin-lee Wu.   

Abstract

MicroRNA-30c (miR-30c) acts as a tumor suppressor or a tumor promoter in various human malignancies. However, the involvement of miR-30c in prostate cancer (PCa) is still unclear. The aim of this study was to investigate the molecular function and the clinical significance of miR-30c in PCa. Expression levels of miR-30c in PCa tissues and cells were detected by quantitative real-time-PCR (qRT-PCR). Additionally, the associations of miR-30c expression with clinicopathological features and prognosis in PCa patients were analyzed. The potential role of miR-30c in tumorigenesis of PCa cells was further evaluated by in vitro cell assays. MiR-30c was significantly down-regulated in PCa tissues and cells compared with the corresponding controls (P<0.05). In addition, the downregulation of miR-30c in PCa tissues was significantly associated with higher Gleason score (P=0.009), advanced pathological stage (P=0.016) and biochemical recurrence (P=0.034). Moreover, Kaplan-Meier survival analysis showed that the reduced expression of miR-30c was correlated with shorter biochemical recurrence-free survival (P=0.023). The multivariate analysis also identified miR-30c as an independent prognostic predictor for biochemical recurrence-free survival in patients with PCa. Furthermore, the enforced expression of miR-30c suppressed proliferation, migration and invasion of PCa cells in vitro. Our data indicated the involvement of miR-30c in PCa progression and suggested its potential role as an independent predictor of biochemical recurrence in PCa. On cellular level, miR-30c may function as a tumor suppressor for PCa cells by inhibiting tumor cell proliferation, migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452717     DOI: 10.1007/s11033-014-3132-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

1.  Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides.

Authors:  Marchina F Benner; Erica Ballabio; Marloes S van Kester; Nigel J Saunders; Maarten H Vermeer; Rein Willemze; Charles H Lawrie; Cornelis P Tensen
Journal:  Exp Dermatol       Date:  2012-08       Impact factor: 3.960

Review 2.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

3.  Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors.

Authors:  Nugroho B Utomo; Chaidir A Mochtar; Rainy Umbas
Journal:  Acta Med Indones       Date:  2012-01

4.  Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells.

Authors:  F Yu; H Deng; H Yao; Q Liu; F Su; E Song
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

5.  MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Authors:  F Germán Rodríguez-González; Anieta M Sieuwerts; Marcel Smid; Maxime P Look; Marion E Meijer-van Gelder; Vanja de Weerd; Stefan Sleijfer; John W M Martens; John A Foekens
Journal:  Breast Cancer Res Treat       Date:  2010-05-19       Impact factor: 4.872

6.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

7.  MicroRNA-mediated regulation of Ubc9 expression in cancer cells.

Authors:  Fangting Wu; Shuomin Zhu; Yanna Ding; William T Beck; Yin-Yuan Mo
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

8.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Authors:  Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

9.  A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers.

Authors:  Christopher L Plaisier; Min Pan; Nitin S Baliga
Journal:  Genome Res       Date:  2012-06-28       Impact factor: 9.043

Review 10.  Histone modifications as markers of cancer prognosis: a cellular view.

Authors:  S K Kurdistani
Journal:  Br J Cancer       Date:  2007-06-26       Impact factor: 7.640

View more
  24 in total

1.  Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.

Authors:  Darina Kachakova; Atanaska Mitkova; Elenko Popov; Ivan Popov; Alexandrina Vlahova; Tihomir Dikov; Svetlana Christova; Vanio Mitev; Chavdar Slavov; Radka Kaneva
Journal:  DNA Cell Biol       Date:  2014-12-18       Impact factor: 3.311

2.  Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.

Authors:  Ziling Huang; Long Zhang; Xianghua Yi; Xiaoting Yu
Journal:  Tumour Biol       Date:  2015-10-24

3.  Methylation and expression levels of microRNA-23b/-24-1/-27b, microRNA-30c-1/-30e, microRNA-301a and let-7g are dysregulated in clear cell renal cell carcinoma.

Authors:  I Gilyazova; E Ivanova; G Gilyazova; I Sultanov; A Izmailov; R Safiullin; V Pavlov; E Khusnutdinova
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

4.  hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3.

Authors:  Jason R Dobson; Hanna Taipaleenmäki; Yu-Jie Hu; Deli Hong; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian; Jitesh Pratap
Journal:  Cancer Cell Int       Date:  2014-08-02       Impact factor: 5.722

5.  Role of microRNA-30c targeting ADAM19 in colorectal cancer.

Authors:  Qian Zhang; Lei Yu; Dandan Qin; Rui Huang; Xiaochen Jiang; Chendan Zou; Qingchao Tang; Yinggang Chen; Guiyu Wang; Xishan Wang; Xu Gao
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

6.  Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.

Authors:  Giovanni Cochetti; Giulia Poli; Gabriella Guelfi; Andrea Boni; Maria Giulia Egidi; Ettore Mearini
Journal:  Onco Targets Ther       Date:  2016-12-13       Impact factor: 4.147

Review 7.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

8.  Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Authors:  Wen-Bin Niu; Shi-Liang Gui; Ying-Li Lin; Xing-Li Fu; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2014-12-08

9.  BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.

Authors:  Xiao-Hui Ling; Zhi-Yun Chen; Hong-Wei Luo; Ze-Zhen Liu; Ying-Ke Liang; Guan-Xing Chen; Fu-Neng Jiang; Wei-DE Zhong
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

10.  Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.

Authors:  Guilherme Rabinowits; Michaela Bowden; Ludmila M Flores; Sigitas Verselis; Victoria Vergara; Vickie Y Jo; Nicole Chau; Jochen Lorch; Peter S Hammerman; Tom Thomas; Laura A Goguen; Donald Annino; Jonathan D Schoenfeld; Danielle N Margalit; Roy B Tishler; Robert I Haddad
Journal:  Front Oncol       Date:  2017-08-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.